The Top 5 Biosimilar Articles for the Week of October 18

Gary Lyman, MD, MPH, Explores the Progress With Oncology Biosimilars

October 17th 2021

By Skylar Jeremias

Oncology biosimilars are broadly in use for good reason: They're absolutely vital for cost reduction and access, but efforts are needed to promote uptake of these agents, says Gary Lyman, MD, MPH, in this interview.

Investigators Review Marketed Adalimumab Biosimilars for Switching Differences

October 16th 2021

By Deana Ferreri, PhD

Investigators in Spain said they found no significant differences in outcomes for patients who switched from adalimumab originator to 1 of multiple adalimumab biosimilars.

FDA Grants Interchangeable Status for Boehringer Ingelheim's Adalimumab Biosimilar (Cyltezo)

October 15th 2021

By Tony Hagen

The interchangeable designation allows pharmacists more flexibility to dispense this potentially money-saving product and gives Boehringer Ingelheim a marketing edge.

The Top 5 Biosimilar Articles for the Week of October 11

October 15th 2021

Here are the top 5 biosimilar articles for the week of October 11, 2021.

Dose Adjustment, Infusion Interval Changes Hold Value for Patients With AS Treated With CT-P13

October 14th 2021

By Tony Hagen

Investigators said the RAAS study filled in missing information on the value of dose modulations and infusion interval changes for patients with ankylosing spondylitis (AS) treated with CT-P13 (Remsima, Inflectra).

Biosimilars Forum Launches State-by-State Savings Calculator

October 13th 2021

By Tony Hagen

An interactive tool from Biosimilars Forum, an industry group, uses data from Pacific Research Institute to calculate potential biosimilar savings based on 75% market share.

Polpharma Biologics Executives Discuss Ranibizumab Biosimilar and Other Product Candidates

October 13th 2021

The Center for Biosimilars® speaks with Polpharma Biologics executives Alex Moulson, vice president of Development, and Pawel Lewinski, head of Portfolio and Commercial Strategy, about the company's biosimilar pipeline.

EU Commission Enters Comment Phase of Plan to Improve Pharmaceutical Competition, Access

October 12th 2021

By Tony Hagen

The European Commission is collecting comment on its multifaceted blueprint for broadening access to biologics and generic drugs and stimulating competition.

Ivo Abraham, PhD, Discusses G-CSF Biosimilars, Such as Neulasta Onpro

October 11th 2021

By Skylar Jeremias

Ivo Abraham, PhD, a professor with University of Arizona Health Sciences in the Department of Pharmacy Practice, outlines the current trajectory and savings potential for granulocyte-colony stimulating factor (G-CSF) biosimilars and Neulasta Onpro (pegfilgrastim).

Not So Different: Tactics for Increasing Patient and Provider Confidence in Biosimilars

October 10th 2021

Kirollos Hanna, PharmD, from the University of Minnesota Medical Center, explains how his practice has worked to inform patients and providers about biosimilars and improve their confidence in the utilization of biosimilars.